Form 4 for LRMR Larimar Therapeutics, Inc.
Accepted 2022-09-20 00:00:00 ET · period of report 2022-09-16 · accession 0001062993-22-019753 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-20 | 2022-09-16 | LRMR | Hamilton Thomas Edward | Dir | P - Purchase | $3.15 | +317.5K | 507.6K | +167% | +$1000.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-16 | P | A | 317,460 | $3.15 | 507,590 | D | — | — | (F1) Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on September 16, 2022. |